Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2

Trial Profile

Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms DREAM; GERCOR DREAM
  • Most Recent Events

    • 20 Jan 2018 Results of a post-hoc analysis evaluating clinical outcomes according to KRAS mutational status and Primary tumor sidedness presented at the 2018 Gastrointestinal Cancers Symposium
    • 07 Jun 2016 Results of health-related quality of life data presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 13 Oct 2015 Results (n=452) published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top